RESUMO
BACKGROUND AND AIMS: Hepatitis C virus (HCV) infection is a challenge to prevent and treat because of the rapid development of drug resistance and escape. Viral entry is required for initiation, spread, and maintenance of infection, making it an attractive target for antiviral strategies. METHODS: Using genetic immunization, we produced four monoclonal antibodies (mAbs) against the HCV host entry factor CD81. The effects of antibodies on inhibition of HCV infection and dissemination were analyzed in HCV permissive human liver cell lines. RESULTS: The anti-CD81 mAbs efficiently inhibited infection by HCV of different genotypes as well as a HCV escape variant selected during liver transplantation and re-infecting the liver graft. Kinetic studies indicated that anti-CD81 mAbs target a post-binding step during HCV entry. In addition to inhibiting cell-free HCV infection, one antibody was also able to block neutralizing antibody-resistant HCV cell-cell transmission and viral dissemination without displaying any detectable toxicity. CONCLUSION: A novel anti-CD81 mAb generated by genetic immunization efficiently blocks HCV spread and dissemination. This antibody will be useful to further unravel the role of virus-host interactions during HCV entry and cell-cell transmission. Furthermore, this antibody may be of interest for the development of antivirals for prevention and treatment of HCV infection.
Assuntos
Anticorpos Monoclonais/imunologia , Hepacivirus/imunologia , Hepacivirus/fisiologia , Anticorpos Anti-Hepatite C/imunologia , Imunização , Tetraspanina 28/imunologia , Internalização do Vírus , Animais , Anticorpos Neutralizantes/imunologia , Membrana Celular/imunologia , Hepatite C/imunologia , Hepatite C/virologia , Humanos , Ratos , Ratos Wistar , Proteínas do Envelope Viral/imunologiaRESUMO
Hepatitis C virus (HCV) entry is dependent on coreceptor complex formation between the tetraspanin superfamily member CD81 and the tight junction protein claudin-1 (CLDN1) on the host cell membrane. The receptor tyrosine kinase EGFR acts as a cofactor for HCV entry by promoting CD81-CLDN1 complex formation via unknown mechanisms. We identify the GTPase HRas, activated downstream of EGFR signaling, as a key host signal transducer for EGFR-mediated HCV entry. Proteomic analysis revealed that HRas associates with tetraspanin CD81, CLDN1, and the previously unrecognized HCV entry cofactors integrin ß1 and Ras-related protein Rap2B in hepatocyte membranes. HRas signaling is required for lateral membrane diffusion of CD81, which enables tetraspanin receptor complex assembly. HRas was also found to be relevant for entry of other viruses, including influenza. Our data demonstrate that viruses exploit HRas signaling for cellular entry by compartmentalization of entry factors and receptor trafficking.
Assuntos
Claudina-1/metabolismo , Hepacivirus/fisiologia , Hepatite C/metabolismo , Proteínas Proto-Oncogênicas p21(ras)/metabolismo , Transdução de Sinais , Tetraspanina 28/metabolismo , Internalização do Vírus , Claudina-1/química , Receptores ErbB/genética , Receptores ErbB/metabolismo , Hepatite C/genética , Hepatite C/virologia , Humanos , Ligação Proteica , Multimerização Proteica , Proteínas Proto-Oncogênicas p21(ras)/genética , Tetraspanina 28/química , Tetraspaninas/genética , Tetraspaninas/metabolismoRESUMO
BACKGROUND: A major challenge for antiviral treatment of hepatitis C virus (HCV) infection is viral resistance, potentially resulting from the high variability of HCV envelope glycoproteins and subsequent selection of strains with enhanced infectivity and/or immune escape. METHODS: We used a bioinformatics and functional approach to investigate whether E1/E2 envelope glycoprotein structure and function were associated with treatment failure in 92 patients infected with HCV genotype 1. RESULTS: Bioinformatics analysis identified 1 sustain virological response (R)-related residue in E1 (219T) and 2 non-SVR (NR)-related molecular signatures in E2 (431A and 642V) in HCV genotype 1a. Two of these positions also appeared in minimal networks separating NR patients from R patients. HCV pseudoparticles (HCVpp) expressing 431A and 642V resulted in a decrease in antibody-mediated neutralization by pretreatment sera. 431A/HCVpp entry into Huh7.5 cells increased with overexpression of CD81 and SR-BI. Moreover, an association of envelope glycoprotein signatures with treatment failure was confirmed in an independent cohort (Virahep-C). CONCLUSIONS: Combined in silico and functional analyses demonstrate that envelope glycoprotein signatures associated with treatment failure result in an alteration of host cell entry factor use and escape from neutralizing antibodies, suggesting that virus-host interactions during viral entry contribute to treatment failure.
Assuntos
Biologia Computacional/métodos , Hepatite C/virologia , Proteínas do Envelope Viral/genética , Internalização do Vírus/efeitos dos fármacos , Adulto , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/imunologia , Antivirais/farmacologia , Feminino , Genótipo , Células HEK293 , Hepacivirus/classificação , Hepacivirus/patogenicidade , Hepatite C/tratamento farmacológico , Hepatite C/imunologia , Humanos , Evasão da Resposta Imune , Masculino , Pessoa de Meia-Idade , Mutagênese Sítio-Dirigida , Mutação , Testes de Neutralização , Ribavirina/farmacologia , Relação Estrutura-Atividade , Falha de Tratamento , Proteínas do Envelope Viral/imunologiaRESUMO
UNLABELLED: Scavenger receptor class B type I (SR-BI) is a high-density lipoprotein (HDL) receptor highly expressed in the liver and modulating HDL metabolism. Hepatitis C virus (HCV) is able to directly interact with SR-BI and requires this receptor to efficiently enter into hepatocytes to establish productive infection. A complex interplay between lipoproteins, SR-BI and HCV envelope glycoproteins has been reported to take place during this process. SR-BI has been demonstrated to act during binding and postbinding steps of HCV entry. Although the SR-BI determinants involved in HCV binding have been partially characterized, the postbinding function of SR-BI remains largely unknown. To uncover the mechanistic role of SR-BI in viral initiation and dissemination, we generated a novel class of anti-SR-BI monoclonal antibodies that interfere with postbinding steps during the HCV entry process without interfering with HCV particle binding to the target cell surface. Using the novel class of antibodies and cell lines expressing murine and human SR-BI, we demonstrate that the postbinding function of SR-BI is of key impact for both initiation of HCV infection and viral dissemination. Interestingly, this postbinding function of SR-BI appears to be unrelated to HDL interaction but to be directly linked to its lipid transfer function. CONCLUSION: Taken together, our results uncover a crucial role of the SR-BI postbinding function for initiation and maintenance of viral HCV infection that does not require receptor-E2/HDL interactions. The dissection of the molecular mechanisms of SR-BI-mediated HCV entry opens a novel perspective for the design of entry inhibitors interfering specifically with the proviral function of SR-BI.
Assuntos
Antígenos CD36/metabolismo , Hepacivirus/metabolismo , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Monoclonais/metabolismo , Antígenos CD36/imunologia , Linhagem Celular , HDL-Colesterol/antagonistas & inibidores , HDL-Colesterol/metabolismo , Hepacivirus/imunologia , Hepacivirus/patogenicidade , Hepatite C/prevenção & controle , Humanos , Lipoproteínas HDL/metabolismo , Camundongos , Ratos , Receptores de Lipoproteínas/metabolismoRESUMO
Hepatitis C virus (HCV) infection is a major cause of fibrosis, cirrhosis and hepatocellular carcinoma worldwide and thus an important public health problem. No vaccine is available and the current treatment does not cure all patients. A better understanding of the HCV life cycle will aid in developing new antivirals. HCV entry is defined as the sequence of events initiated by attachment of the virus to its host cell end leading to the release of the viral genome into the cytoplasm. HCV entry into hepatocytes is a highly elaborated process involving many viral and cellular factors. Various cellular factors expressed on the surface of hepatocytes contribute to the early stages of viral attachment and entry. In addition, various intracellular proteins also play an important role during virus internalization. This review focuses on recent findings on the HCV entry process and highlights the factors and signaling pathways involved.
RESUMO
Hepatitis C virus (HCV) is a human hepatotropic virus, but the relevant host factors restricting HCV infection to hepatocytes are only partially understood. We demonstrate that exogenous expression of defined host factors reconstituted the entire HCV life cycle in human nonhepatic 293T cells. This study shows robust HCV entry, RNA replication, and production of infectious virus in human nonhepatic cells and highlights key host factors required for liver tropism of HCV.
Assuntos
Hepacivirus/fisiologia , Tropismo Viral , Linhagem Celular , Humanos , Internalização do Vírus , Liberação de Vírus , Replicação ViralRESUMO
BACKGROUND & AIMS: The development of vaccines and other strategies to prevent hepatitis C virus (HCV) infection is limited by rapid viral evasion. HCV entry is the first step of infection; this process involves several viral and host factors and is targeted by host-neutralizing responses. Although the roles of host factors in HCV entry have been well characterized, their involvement in evasion of immune responses is poorly understood. We used acute infection of liver graft as a model to investigate the molecular mechanisms of viral evasion. METHODS: We studied factors that contribute to evasion of host immune responses using patient-derived antibodies, HCV pseudoparticles, and cell culture-derived HCV that express viral envelopes from patients who have undergone liver transplantation. These viruses were used to infect hepatoma cell lines that express different levels of HCV entry factors. RESULTS: By using reverse genetic analyses, we identified altered use of host-cell entry factors as a mechanism by which HCV evades host immune responses. Mutations that alter use of the CD81 receptor also allowed the virus to escape neutralizing antibodies. Kinetic studies showed that these mutations affect virus-antibody interactions during postbinding steps of the HCV entry process. Functional studies with a large panel of patient-derived antibodies showed that this mechanism mediates viral escape, leading to persistent infection in general. CONCLUSIONS: We identified a mechanism by which HCV evades host immune responses, in which use of cell entry factors evolves with escape from neutralizing antibodies. These findings advance our understanding of the pathogenesis of HCV infection and might be used to develop antiviral strategies and vaccines.
Assuntos
Anticorpos Neutralizantes/imunologia , Hepacivirus/genética , Hepatite C/genética , Internalização do Vírus , Linhagem Celular Tumoral , Hepacivirus/imunologia , Hepatite C/imunologia , Humanos , Masculino , Mutação , Transplantes/virologiaAssuntos
Hepacivirus/fisiologia , Hepatócitos/virologia , Internalização do Vírus , Antivirais/classificação , Antivirais/uso terapêutico , Reposicionamento de Medicamentos , Humanos , Modelos Biológicos , Inibidores de Proteínas Quinases/uso terapêutico , Proteínas Quinases/metabolismo , Proteínas Quinases/fisiologia , Senso de Humor e Humor como AssuntoRESUMO
Hepatitis C virus (HCV) is a major cause of liver disease, but therapeutic options are limited and there are no prevention strategies. Viral entry is the first step of infection and requires the cooperative interaction of several host cell factors. Using a functional RNAi kinase screen, we identified epidermal growth factor receptor and ephrin receptor A2 as host cofactors for HCV entry. Blocking receptor kinase activity by approved inhibitors broadly impaired infection by all major HCV genotypes and viral escape variants in cell culture and in a human liver chimeric mouse model in vivo. The identified receptor tyrosine kinases (RTKs) mediate HCV entry by regulating CD81-claudin-1 co-receptor associations and viral glycoprotein-dependent membrane fusion. These results identify RTKs as previously unknown HCV entry cofactors and show that tyrosine kinase inhibitors have substantial antiviral activity. Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection.